双药效团分子治疗COPD的研究进展

Advances in dual pharmacophore molecule therapy for COPD

慢性阻塞性肺病(COPD)愈来愈威胁人类的健康,发病时会出现多种病理反应,目前现有的治疗药物很难单独改善发病症状,需要联合用药。近年来,研究发展了一些在同一个分子中含有两种或两种以上的药效团的药物分子,这些药效团在体内可同时发挥作用,延长作用时间,减轻疾病症状。本文从药物分子设计、构效关系研究和药理活性分析等方面对双药效团分子治疗COPD的研究进展进行总结。

Chronic obstructive pulmonary disease （COPD） has threatened human health in an increasingly fierce manner. Since there are various pathologic responses during the onset, available drug treatments have difficulties to relieve the symptoms alone, and therefore need to be used jointly. In recent years, studies have discovered that the same molecule containing two or more pharmacophores will have them work together in the body, extending the functioning time and reducing the symptoms comprehensively. This review discusses the research progress of treatments for COPD from perspectives of molecular drug design, structure-activity relationships and pharmacological activity analysis.